8/31/17 Flashcards
Contents of the apical domain of epithelial cells
Enzymes Receptors Ion channels Carrier proteins Special structures: microvilli, sterocilia, motile cilia, nonmotile cilia
Microvilli
Finger-like extensions of the PM and cytoplasm
Increase absorptive SA of the cell
Brush border in tubules, striated border in intestines
Actin filaments anchored to a terminal web of myosin
Stereocilia
Long, immotile microvilli
Hair cells of inner ear, epididymis, and vas deferens
Serve as mechanoreceptors
Made of actin
Motile cilia
9+2 arrangement of microtubules attached to a basal body
Sliding movement is initiated by dynein arms
Forms mucociliary escalator
Nodal cilia: found in embryo, responsible for left/right asymmetry of organs
Kartagener Syndrome
Primary Ciliary Dyskinesia
Recessive disorder of motile cilia
Defect due to loss of inner or outer dynein arms, leads to uncoordinated beating
Poor mucociliary clearance leads to chronic bronchitis and also pneumonia and bronchiectasis
Sinusitis that can cause loss of smell, hearing loss
Immotile sperm that can cause infertility
Impaired nodal cilia leads to situs inversus where organs are mirror images of normal
Primary cilia
Immotile 9-0 arrangement with no dynein or inner doublet
Found in kidneys
Mechanoreceptors that passively bend in response to fluid flow and create Ca2+ influx
Polycystin-1 and 2 genes make them up
Autosomal Dominant Polycystic Kidney Disease
Mutations for the polycstin genes of primary cilia
Enlarged cystic kidneys and can get cysts elsewhere like in pancreas
GLP-1
Made from proglucagon in the intestinal L cells
Levels decreased in type II but respond to it
Decrease gastric emptying and appetite
Increase beta cell proliferation, decrease apoptosis
Neuroprotective, cardioprotection, and promotes bone formation
GIP
Glucose-dependent Insulinotropic Peptide
Secreted by K cells in jejunum
Secretion not decreased in type II but resistant
Similar effects to GLP-1
Not a therapeutic target
GLP-1 analogues (incretin mimetics) vs. DPP-4 inhibitors (incretin enhancers)
Incretin mimetics: Exenatide from Gila Monster and Liraglutide, subcutaneous injections, weight loss, nausea
Incretin enhancers: vildagliptin and Sdagliptin, oral administration, increase GLP-1 levels 2-3 fold, also inhibit cleavage of other proteins from DPP-4, weight neutral, no side effects
Both don’t increase hypoglycemic episodes since effects are glucose-dependent, don’t take if have severe renal probs
Counterregulatory Hormones
Glucagon, catecholamines, growth hormone, cortisol
Increase glycogenolysis, gluconeogenesis, lipolysis, hepatic ketogenesis
Decrease peripheral glucose uptake
Growth hormone and cortisol have dampened effects compared to the other two
Impaired defense against hypoglycemia in type I
After 5 years glucagon response to hypoglycemia is lost and rely on epinephrine from adrenal glands
Hypoglycemia-associated autonomic failure:
Epinephrine response gets blunted after recurring hypoglycemia
Prevention of hypoglycemia can rescue impaired counterregulatory hormone defect, defect is less common in type II
Diabetic Ketoacidosis
Need-
1. Insulin deficiency: leads to increased FA delivery to liver and subsequent movement into mitochondria
- Counterregulatory hormone excess: increases CPT II and conversion to ketone bodies
Characterized by Hyperglycemia and ketonemia
Increased water in urine for higher glucose and ketones lead to dehydration that causes low blood pressure and shock.
Ketones only come from liver, can cross BBB unlike FAs
Clinical symptoms of diabetic ketoacidosis
Nausea, vomiting, thirsty, abdominal pain, shortness of breath
Tachycardia, dehydration, hypotension, respiratory distress, lethargy, possible coma
Pharmacokinetics
Time-dependent changes of drug conc. in body following drug administration
Looks at conc. in plasma, target tissues, etc.
4 Factors affecting pharmacokinetics
Absorption
Distribution
Metabolism
Excretion
Drug Absorption
Most drugs absorbed by passive diffusion, not saturable, first order kinetics
Need neutral form to pass membranes, weak acid start neutral but weak base needs to be deprotonated to cross
High pH makes harder to absorb weak acids, easier to absorb weak bases
Bioavailability
Oral drugs exposed to liver and are metabolized before reach rest of body (first pass effect)
IV administration directly enters systemic circulation and has access to rest of body
Bioavailability = area under curve (oral) / area under curve (injected) * 100
Time vs. plasma conc.
Fraction of orally administered drug that reaches systemic circulation
Factors for Bioavailability
Some drugs not stable in acidic environment
Not efficiently absorbed in the GIT
Microorganisms can metabolize
P450 enzymes in GIT metabolize some drugs
First pass Effect in liver
Drug Distribution blood flow
Blood flow: brain, liver, and kidneys have higher blood flows than muscle, skin, and fat
Capillary Permeability: endothelial cells in liver have large fenestrations for drugs, brain has tight junctions that limit
Binding of drugs to plasma proteins and tissues is reversible/nonselective and slows drug transfer
Two compartment model of drug distribution in plasma after IV
Alpha Phase: initial rapid decline in plasma drug conc. due to distribution from circulation into the peripheral tissues, ends when form pseudo equilibrium of drug conc. between circulation and peripheral tissues
Beta phase: gradual decrease in plasma conc. due to drug metabolism and excretion
Volume of Distribution
Amount of drug in the body / drug conc. in plasma
Drug Metabolism
Enzymatic Modification that normally inactivates drugs and increase water solubility to enhance Secretion by kidneys
Can activate prodrugs to make them active
Mainly liver but also intestines, kidneys, lungs, skin, and blood
Phase I: cytochrome P-450s, do oxidation, hydroxylation, dealkylation, or deamination
Phase II: conjugation with addition of large substituent group like sulfate or glucuronidation, makes more polar
Cytochrome P450s
Many kinds, expression is regulated , often membrane bound
Substrates often have high lipid solubility
Use NADPH to reduce substrate
Inhibited by imidazole containing drugs, antibiotics like erythromycin, grapefruit juice, and more
Drug Excretion
Uncharged forms of drugs are reabsorbed better in the kidneys
Metabolism makes drug metabolites ionized or hydrophilic to improve excretion into urine
Increases or decreases in urine pH will impact absorption of weak acids or bases
Kinetics of Metabolism
Rate of metabolism:
V = vmax [c] / (Km + [c])
First order: when [c] < Km
V = vmax/Km * [c]
lnC = lnCo - kt
t1/2 = ln2 / k or 0.693 / k, is independent of conc.
Describes conc. in blood after IV, most common
Zero order: when [c] > Km V = vmax/Km C = Co - kt t1/2 = 1/2 * Co / k If elimination becomes saturated
2 parameters for Pharmacokinetics
Volume of distribution and clearance
Clearance
Volume of plasma cleared of drug per unit time (L/hr.)
Rate of elimination: CL * [C]
t1/2 = 0.693 Vd / CL
CL is based on sum of clearance by liver, kidneys, and other excretion pathways